Halozyme Therapeutics CEO Helen Torley reports sale of $6 million in shares
HALO•Halozyme Therapeutics CEO Helen Torley sold 60,000 common shares between Nov. 12 and 16, 2026, at prices ranging from $96.848 to $101.72 per share.
1. Share transactions
Torley also exercised options for 60,000 common shares at exercise prices of $16.65 and $18.41 during the same period. Her direct common stock ownership remained unchanged at 767,780 shares after the transactions.




